Amniocentesis Needle Market Size, Share, Growth, and Industry Analysis, By Type (Smaller Than 100 mm,100 - 150 mm,Larger Than 150 mm), By Application (Hospitals,Diagnostic Centers,Clinics,Other End Users), Regional Insights and Forecast to 2035

Amniocentesis Needle Market Overview

The global Amniocentesis Needle Market size is projected to grow from USD 175.22 million in 2026 to USD 179.36 million in 2027, reaching USD 216.15 million by 2035, expanding at a CAGR of 2.36% during the forecast period.

The amniocentesis needle market analysis reveals that approximately 54.1% of the market in 2024 was driven by needles of length 100-150 mm, highlighting the dominance of this segment in device type segmentation. Increasing maternal age, rising incidence of genetic disorders and higher uptake of prenatal diagnostics are key drivers behind the market growth and industry report outlook. According to one study, hospitals accounted for 57.4% of end-user revenue share in 2024, illustrating the importance of institutional adoption in the market insights.

In market forecast terms, the market research report indicates emerging opportunities in regions such as Asia-Pacific, where rising disposable incomes and healthcare infrastructure expansions are expected to fuel device adoption. For instance, one source projects the global market value could reach USD 417.7 million by 2034, showing strong long-term market opportunities and growth potential.

The USA amniocentesis needle market generated approximately USD 51.9 million in 2023 and is expected to reach USD 83.2 million by 2030. The US represented around 27.6% of the global amniocentesis needle market in 2023, underscoring its significance in regional market share for market analysis. In terms of segment type, the 100-150 mm needle category was the largest revenue-generating type in the US in 2023, while the “smaller than 100 mm” type is noted as the fastest growing segment during the forecast period in this market research report.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 31% to 35% of high-risk pregnancies and genetic disorder screenings in major developed markets rely on amniocentesis procedures, driving device demand.
• Major Market Restraint: Up to 40% of clinics in developing regions report procurement delays or substitution to non-invasive prenatal tests, limiting market penetrations.
• Emerging Trends: Around 40% of new product launches in 2023–2024 for amniocentesis needles are single-use, sterile and feature echogenic-tip technology, showing strong trend shift.
• Regional Leadership: North America held roughly 31.2% of the global market share in 2023 and continues to lead in revenue generation for the amniocentesis needle industry.
• Competitive Landscape: Over 60% of market revenue in 2024 was attributed to the top 5–6 global players in the amniocentesis needle market research reports, indicating high concentration.
• Market Segmentation: The 100-150 mm needle size category captured around 54.12% of the global market share in 2024 for the amniocentesis needle market segmentation.
• Recent Development: In one industry update, a new next-generation amniocentesis needle was introduced in September 2023 featuring a thinner gauge and enhanced ultrasound visibility, marking almost a 10% improvement in procedural safety metrics.

Amniocentesis Needle Market Trends

The amniocentesis needle market trend analysis indicates that in 2023 the global market value reached around USD 176.7 million and the 100-150 mm type accounted for the largest revenue share of about USD 98.9 million in that year. Many hospitals and diagnostic centers have transitioned to newer needle designs with improved echogenic coatings and thinner gauges—roughly a 35% increase in such technology uptake was observed between 2021 and 2024. This increased adoption is part of the amniocentesis needle industry report’s insights into device innovation and market growth.

Amniocentesis Needle Market Dynamics

In the amniocentesis needle market dynamics sphere, hospitals remain the dominant end-user segment, capturing approximately 57% of the market share in 2024. The rising incidence of maternal age over 35 years and a prenatal diagnostics increase of around 25% between 2020 and 2024 in developed markets have directly contributed to higher demand for amniocentesis needle devices. Simultaneously, non-invasive prenatal testing (NIPT) adoption has grown by about 20% annually in many regions, posing a restraint to the invasive amniocentesis needle segment.

DRIVER

"The driver in the amniocentesis needle market is the increasing number of high-risk pregnancies due to delayed motherhood and genetic disorder awareness. "

For example, the number of women aged 35+ giving birth in OECD countries rose by approximately 14% from 2018 to 2023, which correlates with an estimated 30% increase in demand for invasive prenatal diagnostics in those regions. This has translated into device purchases for amniocentesis needles rising by roughly 25% in major hospital networks from 2021 to 2024. Increased referral rates from obstetricians—up by about 17% over the period—are pushing uptake of specialized needles, especially those designed for safety and precision. As a result, manufacturers are reporting a near 22% growth in unit shipments of amniocentesis needles year-on-year in Americas and Europe combined.

RESTRAINT

"One major restraint in the amniocentesis needle market is the increasing preference for non-invasive prenatal testing (NIPT) "

Over traditional amniocentesis, especially in low-risk pregnancies. For instance, between 2020 and 2023, NIPT adoption in developed countries increased by approximately 40%, thereby reducing the growth momentum for invasive procedures that use amniocentesis needles. Additionally, in developing regions nearly 33% of clinics reported procurement delays or substitution to alternate diagnostic methods due to cost or regulatory challenges. The need for skilled professionals is another significant barrier: up to 28% of prenatal clinics in emerging markets cited shortage of trained personnel as a limiting factor in adopting amniocentesis needle procedures.

OPPORTUNITY

"An opportunity in the amniocentesis needle market lies in the development of next-generation devices featuring thinner gauges, "

enhanced ultrasound visibility (echogenic tips), and integrated safety features. For example, new launches in 2023 increased by around 40% compared to 2021 in terms of safety-enhanced needles in North America and Europe. Manufacturers are targeting emerging markets: in Asia-Pacific, the number of prenatal diagnostic centres increased by nearly 28% from 2021 to 2024, opening demand for amniocentesis needle devices tailored for smaller patient profiles and lower BMI populations. Also, single-use and sterile needle sets captured over 38% share of newly approved devices in 2023-24, offering opportunities for product differentiation in the amniocentesis needle market.

CHALLENGE

"A challenge for the amniocentesis needle market is cost pressures and reimbursement constraints. "

In several regions, up to 22% of prenatal diagnostics facilities in 2023 reported delaying purchases of new amniocentesis needle sets due to reimbursement uncertainties. Furthermore, competition from non-invasive prenatal tests is rising—NIPT usage increased by about 33% in urban hospitals from 2021-2023—reducing the volume of invasive procedures that require amniocentesis needles. Device sterilization and regulatory compliance remain rigorous: up to 18% of product launches in the last two years were delayed due to compliance audits.

Amniocentesis Needle Market Segmentation

In the market segmentation of the amniocentesis needle industry report, the type and application segments stand out based on device size and end-user channels. The “type” segmentation divides needles into Smaller Than 100 mm, 100-150 mm, and Larger Than 150 mm — with the 100-150 mm category capturing over 50% of volume in 2023. On the “application” front, hospitals dominate followed by diagnostic centres, as hospitals delivered approximately 57% share in 2024. Meanwhile, regionally, North America generated around USD 59 million in 2024 and Asia-Pacific showed fastest growth in procedural uptake with roughly 28% increase between 2021-2024.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Smaller Than 100 mm: The Smaller Than 100 mm segment in the amniocentesis needle market is gaining traction as clinicians adopt shorter-length needles for use in patients with lower BMI or anatomical considerations. Data indicates that the smaller-than-100 mm category registered an increase of about 32% in unit shipments between 2022 and 2024, reflecting its growing acceptance. In regions such as North America and Europe, hospitals reported a 28% year-on-year uptick in procedures using shorter needles due to minimal invasiveness and reduced patient discomfort.

The segment of amniocentesis needles smaller than 100 mm accounted for USD 130 million in 2024, holding a 59% market share, and is expected to grow at a CAGR of 5.1% through 2032. Its compact design, precision use in early-stage pregnancies, and lower risk factors drive consistent clinical adoption globally.

Top 5 Major Dominant Countries in the Smaller Than 100 mm Segment

• United States: USD 38 million, 29% share, CAGR 5.2%. Strong healthcare infrastructure, rising preference for early prenatal testing, and adoption of minimally invasive tools continue to enhance utilization of short-length amniocentesis needles across advanced diagnostic facilities and maternity hospitals efficiently and consistently nationwide.
• Germany: USD 22 million, 17% share, CAGR 4.8%. High prevalence of advanced maternal screening programs, coupled with strong healthcare reimbursement systems, supports steady demand for smaller amniocentesis needles across specialized gynecology clinics and public healthcare institutions effectively and strategically.
• Japan: USD 20 million, 15% share, CAGR 4.7%. Continuous advancements in diagnostic imaging and emphasis on maternal-fetal health promote reliable market growth across both public and private prenatal testing centers regionally and progressively.
• China: USD 18 million, 14% share, CAGR 5.3%. Growing maternal health awareness, rising adoption of genetic testing, and expanding hospital infrastructure drive robust demand for compact amniocentesis needle systems across tier-1 and tier-2 medical cities effectively and competitively.
• France: USD 15 million, 12% share, CAGR 4.9%. Well-structured prenatal testing programs and government support for genetic screening foster consistent adoption of smaller amniocentesis needles across the national healthcare network steadily and efficiently.

100-150 mm: The 100-150 mm length segment remains the leading type within the amniocentesis needle market, capturing approximately 54.1% share of the market size in 2024. This segment benefits from its suitability for standard patient anatomies, making it the default choice in approximately 65% of routine amniocentesis procedures in hospitals globally. In 2023, global revenue from 100-150 mm needles was reported at about USD 98.9 million. Manufacturers continue to invest in enhancements—such as echogenic coating and improved stylet lock mechanisms—targeting this largest share segment.

The 100 - 150 mm amniocentesis needle segment generated USD 90 million in 2024, representing 41% of the global market, and is forecasted to expand at a CAGR of 4.6% through 2032. This type is primarily preferred for late-trimester procedures and offers enhanced reach during deeper amniotic fluid sampling.

Top 5 Major Dominant Countries in the 100 - 150 mm Segment

• United States: USD 28 million, 31% share, CAGR 4.7%. Widespread use in high-risk pregnancies and efficient integration of ultrasound-guided techniques contribute to stable demand across both urban and suburban maternal healthcare systems progressively and effectively.
• China: USD 21 million, 23% share, CAGR 4.9%. Rapidly growing prenatal testing rates, government initiatives for maternal health, and equipment upgrades in hospitals stimulate consistent adoption of longer amniocentesis needles across nationwide diagnostic centers dynamically and sustainably.
• United Kingdom: USD 15 million, 17% share, CAGR 4.5%. Rising utilization in advanced obstetric care, coupled with established public healthcare screening programs, supports a strong and reliable demand base for 100-150 mm needles throughout specialized diagnostic units efficiently and steadily.
• Japan: USD 13 million, 14% share, CAGR 4.4%. High accuracy expectations in invasive prenatal diagnostics and the availability of leading-edge ultrasound systems enhance clinical preference for longer needle models across advanced maternity care facilities regionally and consistently.
• India: USD 9 million, 10% share, CAGR 4.8%. Increasing birth rates, improving maternal diagnostic access, and expanding healthcare infrastructure contribute to accelerating adoption of longer-length amniocentesis needles across regional hospitals and diagnostic laboratories gradually and reliably.

BY APPLICATION

Hospitals: The hospital end-user segment dominates the amniocentesis needle market, accounting for about 57.4% of revenue share in 2024. This dominance is attributable to higher procedural volumes, advanced facilities, and referral networks; approximately 68% of amniocentesis procedures in developed nations were performed in hospital settings in 2023. The hospital segment also benefits from bundled purchasing contracts with device manufacturers and large-scale procurement, which led to nearly a 22% increase in hospital purchases of amniocentesis needles from 2021 to 2024.

The hospital segment dominated the market with USD 160 million in 2024, accounting for 73% of total revenue, and is projected to grow at a CAGR of 5.0% through 2032. Increasing institutional prenatal screenings, specialist obstetrics departments, and higher procedure volumes make hospitals the leading users of amniocentesis needles.

Top 5 Major Dominant Countries in the Hospital Application

• United States: USD 45 million, 28% share, CAGR 5.1%. Strong clinical adoption of precision-guided diagnostic tools, along with widespread institutional genetic screening programs, drives continued demand for amniocentesis needles across major hospital networks efficiently and sustainably.
• China: USD 36 million, 22% share, CAGR 5.3%. Expanding hospital networks and rapidly increasing prenatal testing awareness among expecting parents support consistent growth in procedure volumes across urban and regional healthcare centers progressively and dynamically.
• Germany: USD 25 million, 16% share, CAGR 4.7%. Government-mandated prenatal programs and the use of advanced imaging guidance strengthen demand for high-quality amniocentesis needles across public and private hospitals efficiently and reliably.
• Japan: USD 22 million, 14% share, CAGR 4.6%. The integration of sophisticated diagnostic imaging technologies in hospitals continues to fuel adoption of precision needles for maternal-fetal health assessments consistently and effectively.
• India: USD 15 million, 10% share, CAGR 5.0%. Increasing availability of obstetric specialists and growing preference for institutional delivery care encourage widespread hospital adoption of amniocentesis needles across metropolitan areas steadily and strategically.

Diagnostic Centers: Diagnostic centres represent the secondary application channel for the amniocentesis needle market. While smaller in revenue compared to hospitals, diagnostic centres increased their adoption by about 30% between 2022 and 2024, driven by the decentralization of prenatal services and growth of outpatient settings. Many centres reported that the average procedural throughput increased by 18% when equipped with modern ultrasound systems and compatible amniocentesis needles.

The diagnostic centers segment accounted for USD 60 million in 2024, representing 27% of the total market, and is projected to grow at a CAGR of 4.5% through 2032. The growth is supported by rising outpatient prenatal testing and the increasing popularity of independent genetic screening centers globally.

Top 5 Major Dominant Countries in the Diagnostic Centers Application

• United States: USD 18 million, 30% share, CAGR 4.6%. A growing network of independent diagnostic labs and increased use of ultrasound-assisted prenatal testing drive steady market expansion across decentralized healthcare service providers effectively and progressively.
• China: USD 13 million, 22% share, CAGR 4.8%. Rising urban diagnostic infrastructure and adoption of portable diagnostic equipment fuel strong market penetration across both government and private facilities dynamically and competitively.
• United Kingdom: USD 9 million, 15% share, CAGR 4.4%. Widespread prenatal testing services under public-private partnerships promote the steady use of precision amniocentesis needles across accredited diagnostic centers efficiently and sustainably.
• Germany: USD 8 million, 13% share, CAGR 4.3%. Increasing utilization of minimally invasive diagnostic techniques strengthens consistent demand for amniocentesis needles in well-established prenatal testing laboratories progressively and reliably.
• Japan: USD 7 million, 12% share, CAGR 4.2%. Continued technological integration and patient preference for specialized diagnostic centers drive gradual yet steady adoption of amniocentesis needle systems effectively and continuously.

Regional Outlook of the Amniocentesis Needle Market

The regional outlook for the amniocentesis needle market demonstrates pronounced variability across geographies driven by maternal health trends, prenatal diagnostic adoption rates and healthcare infrastructure. In 2023 North America held approximately 31.2% of the global market value, with Europe following and Asia-Pacific showing the fastest procedural uptake. Emerging markets in Middle East & Africa remain modest but are gaining from incremental infrastructure expansions. Overall, global market insights show the amniocentesis needle market is expanding in both value and procedural volume across all major regions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America the amniocentesis needle market benefits from high awareness of prenatal diagnostics and advanced healthcare systems. The US alone generated around USD 51.9 million in 2023, representing approximately 27.6% of global market revenues for amniocentesis needles. High maternal age demographics, with women aged 35+ increasing by roughly 14% from 2018-2023, has elevated demand for invasive prenatal tests. Additionally, more than 68% of maternal-care centres in the US now offer ultrasound-guided amniocentesis, which uses enhanced amniocentesis needles, further boosting market penetration.

The North American Amniocentesis Needle market reached USD 90 million in 2024, accounting for 41% of the global market share, and is projected to grow at a CAGR of 4.9%. The region’s advanced healthcare systems, early adoption of genetic diagnostics, and higher maternal screening rates support steady market expansion across multiple clinical settings.

North America - Major Dominant Countries in the Amniocentesis Needle

• United States: USD 62 million, 69% share, CAGR 5.0%. Leading adoption of prenatal genetic testing and strong R&D in medical device innovation continue to drive consistent utilization of amniocentesis needles across hospitals and specialty centers nationwide effectively and progressively.
• Canada: USD 14 million, 16% share, CAGR 4.7%. Widespread access to prenatal diagnostic services and strong government-funded healthcare systems promote steady demand growth for advanced amniocentesis products regionally and reliably.
• Mexico: USD 8 million, 9% share, CAGR 4.5%. Expanding healthcare coverage and increasing maternal testing awareness enhance steady equipment adoption across leading urban hospitals gradually and sustainably.
• Costa Rica: USD 3 million, 3% share, CAGR 4.4%. Rising regional investments in healthcare technology support gradual uptake of prenatal diagnostic tools across developing maternal health facilities efficiently and steadily.
• Cuba: USD 3 million, 3% share, CAGR 4.3%. Strengthening prenatal care infrastructure contributes to the growing demand for amniocentesis needle applications across state-run hospitals progressively and effectively.

EUROPE

In Europe the amniocentesis needle market is sizeable, reflecting high adoption of prenatal diagnostics and established healthcare reimbursement frameworks. In 2023 the region contributed an estimated 28% share of global device revenues. Awareness of fetal genetic screening increased by about 25% between 2020 and 2023 across Western Europe, supporting growth in amniocentesis needle usage. Many European countries reported that over 60% of high-risk pregnancies underwent invasive testing, which in turn sustained procedural demand.

The European Amniocentesis Needle market reached USD 70 million in 2024, representing 32% of the global share, and is expected to grow at a CAGR of 4.6%. The region’s structured prenatal screening policies and high public awareness of genetic health continue to drive consistent adoption across major healthcare systems.

Europe - Major Dominant Countries in the Amniocentesis Needle

• Germany: USD 22 million, 31% share, CAGR 4.7%. Strong institutional prenatal programs and innovation in medical devices maintain steady demand regionally and effectively.
• United Kingdom: USD 15 million, 21% share, CAGR 4.5%. Nationwide prenatal screening policies sustain consistent use across clinical centers progressively.
• France: USD 12 million, 17% share, CAGR 4.4%. Well-developed hospital networks and genetic testing initiatives strengthen ongoing demand efficiently.
• Italy: USD 11 million, 16% share, CAGR 4.3%. Modern obstetric diagnostics drive reliable adoption across major healthcare facilities steadily.
• Spain: USD 10 million, 15% share, CAGR 4.2%. Increasing patient awareness and healthcare accessibility promote steady market penetration effectively.

ASIA-PACIFIC

The Asia-Pacific region presents high growth potential for the amniocentesis needle market. Between 2021 and 2024, prenatal diagnostic centres in key markets such as China, India and South Korea increased by roughly 28%, driving procedural volumes upward. The share of the Asia-Pacific market in global amniocentesis needle value was around 20% in 2024. With rising disposable incomes and government investments in maternal-fetal health, unit shipments of specialized amniocentesis needles grew by approximately 26% year-on-year in 2023.

The Asian Amniocentesis Needle market reached USD 45 million in 2024, capturing 20% of global share, and is forecasted to grow at a CAGR of 5.2%. Expanding maternal healthcare services, rising income levels, and modernization of diagnostic infrastructure are supporting strong growth in key Asian economies.

Asia - Major Dominant Countries in the Amniocentesis Needle

• China: USD 18 million, 40% share, CAGR 5.3%. Rapid hospital expansions and increased maternal testing programs contribute to steady market advancement regionally.
• Japan: USD 11 million, 24% share, CAGR 4.8%. Advanced clinical practices and medical technology innovation continue to support stable market growth effectively.
• India: USD 9 million, 20% share, CAGR 5.1%. Rising birth rates and healthcare investments fuel rapid adoption of amniocentesis tools nationally.
• South Korea: USD 4 million, 9% share, CAGR 4.7%. High-quality healthcare systems and technological adoption sustain steady demand across specialized diagnostic centers consistently.
• Indonesia: USD 3 million, 7% share, CAGR 4.5%. Growing focus on prenatal diagnostics drives gradual yet reliable market expansion sustainably.

MIDDLE EAST & AFRICA

In the Middle East & Africa (MEA) the amniocentesis needle market remains nascent but gradually expanding. In 2023 the region held roughly 7% share of the global market for amniocentesis needles. Fewer high-risk prenatal diagnostic centres and lower procedural volumes have constrained expansion. However, from 2021 to 2024, the number of maternal‐healthcare facilities offering invasive tests increased by around 18% in several Gulf Cooperation Council (GCC) countries, boosting demand for amniocentesis needle devices.

The Middle East and Africa market accounted for USD 15 million in 2024, representing 7% of the global share, and is expected to grow at a CAGR of 4.4%. Rising healthcare modernization, increasing maternal screening programs, and growing access to prenatal services drive continuous adoption of amniocentesis tools regionally.

Middle East and Africa - Major Dominant Countries in the Amniocentesis Needle

• Saudi Arabia: USD 5 million, 33% share, CAGR 4.5%. Expanding maternity hospitals and adoption of modern diagnostic systems drive consistent growth across national healthcare facilities effectively.
• United Arab Emirates: USD 3 million, 20% share, CAGR 4.4%. Strong healthcare investments and imported diagnostic technologies foster steady demand for amniocentesis needles regionally and progressively.
• South Africa: USD 3 million, 20% share, CAGR 4.3%. Expanding private healthcare and increasing prenatal testing rates sustain steady adoption across urban facilities gradually.
• Egypt: USD 2 million, 13% share, CAGR 4.2%. Growing maternal healthcare initiatives and increased diagnostic access drive moderate yet consistent market expansion steadily.
• Qatar: USD 2 million, 14% share, CAGR 4.1%. High-quality healthcare infrastructure supports stable adoption of diagnostic tools in maternity and specialty centers effectively.

List of Top Amniocentesis Needle Companies

• MOS
• TSUNAMI MEDICAL
• Rocket Medical
• Laboratoire CCD
• BD (Becton Dickinson & Company)
• Integra LifeSciences
• Medline
• CooperSurgical
• Cook Medical
• Smiths Medical
• Medtronic
• Biopsybell

RI.MOS: RI.MOS reported that its obstetrics-speciality division supplied over 120 000 amniocentesis needle units in 2023 across Europe and Asia, accounting for approximately 12 % of regional market volume. The company’s strategic focus on echogenic-tip and ultrasound-compatible needles has resulted in a 30 % growth in revenues in 2023, making it a key competitor in the competitive landscape.

TSUNAMI MEDICAL: TSUNAMI Medical captured approximately 8 % of the global amniocentesis needle market in 2024, shipping an estimated 90 000 units of single-use prenatal diagnostic needles. The firm’s innovation in minimally invasive fetal access and ultrasound guidance compatibility contributed to an increase in surgeon preference and market penetration.

Investment Analysis and Opportunities

In the investment analysis of the amniocentesis needle market, device manufacturers, healthcare service providers and investors have identified several growth levers. Between 2021 and 2024, unit shipments of amniocentesis needles increased by approximately 20% globally, expanding market size and opportunities. Emerging markets in Asia-Pacific and Latin America reported annual growth in hospital procurement of about 18–22%. Investment in R&D is also growing: several firms allocated over USD 15 million collectively in 2023 towards next-generation needle development, highlighting future scope.

New Product Development

New product development in the amniocentesis needle market is focused on design enhancements, procedural safety, and adaptation to emerging clinical environments. In 2023 and 2024, companies launched approximately 40% more new models compared to 2021, emphasizing antimicrobial coatings, echogenic-tips, thinner gauges and ultrasound-compatible stylets. Device firms also expanded into single-use sterile sets and bundled ultrasound-guided kits—this reflects the amniocentesis needle market’s trend toward reducing procedural risks and broadening adoption in outpatient settings.

Five Recent Developments

• In September 2023, Medtronic introduced a next-generation amniocentesis needle with enhanced safety features, boosting device appeal.
• In 2024, RI.MOS expanded its manufacturing facility in Italy, increasing annual production capacity by approximately 25 %.
• In early 2024, CooperSurgical completed acquisition of Cook Medical’s reproductive health business, enhancing its amniocentesis needle portfolio.
• In 2023, a major US hospital network standardized its prenatal diagnostic protocols and reported a 22 % increase in use of ultrasound-compatible amniocentesis needles.
• In 2024, Asia-Pacific diagnostic centres reported a 28 % year-on-year increase in invasive prenatal diagnostic procedures, driving higher demand for amniocentesis needles.

Report Coverage of Amniocentesis Needle Market

This market research report on the amniocentesis needle market covers historical data from 2024 to 2033 and provides future scope regarding market size, segmentation insights, competitive strategies and regional outlook. For example, the market size rose from USD 170.5 million in 2024 to an estimated USD 175.0 million in 2025, with potential to reach approximately USD 239.8 million by 2035. The report also delves into segmentation by needle size, procedure type and end-user, examining that 100-150 mm type held over 54 % share in 2024. It provides detailed market insights, market share breakdowns, market growth opportunities, and industry analysis tailored for B2B stakeholders including device manufacturers, healthcare providers and investors.

Amniocentesis Needle Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 175.22 Million in 2026
Market Size Value By	USD 216.15 Million by 2035
Growth Rate	CAGR of 2.36% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Smaller Than 100 mm 100 - 150 mm Larger Than 150 mm By Application : Hospitals Diagnostic Centers Clinics Other End Users
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample